Fertility preservation and preimplantation genetic assessment for women with breast cancer.

Fertility preservation and preimplantation genetic assessment for women with breast cancer. Cryobiology. 2019 Dec 18;: Authors: Sciorio R, Anderson RA Abstract Breast cancer is the most common cancer diagnosed among reproductive aged women, and its treatment can compromise future fertility. Options for fertility preservation include oocyte or embryo cryopreservation after ovarian stimulation (OS), which are the most established choices and are applicable for adult women with cancer. Ovarian tissue freezing may also be appropriate, as it offers potentially the least delay. The recognisation of the role of BRCA1 and BRCA2 mutations in some women has led to the involvement of preimplantation genetic diagnosis (PGD), recently renamed preimplantation genetic testing for monogenic disorder (PGT-M), whereby embryos are created by IVF and cell(s) are removed and genetically analyzed for specific disease-related mutations. PGT-M offers a valid option for women wishing to avoid transmission of the predisposition for hereditary breast cancer to their offspring. The aim of this paper is to provide an overview of the factors that influence fertility preservation in newly diagnosed breast cancer patients, and to illustrate the option of PGT-M to enable conception of an unaffected child. PMID: 31863734 [PubMed - as supplied by publisher]
Source: Cryobiology - Category: Biology Authors: Tags: Cryobiology Source Type: research